Drugs /

capecitabine

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
capecitabine
Trade Name(s):
Xeloda
NCI Definition [1]:
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for capecitabine

Capecitabine has been investigated in 118 clinical trials, of which 94 are open and 24 are closed. Of the trials investigating capecitabine, 23 are phase 1 (16 open), 15 are phase 1/phase 2 (11 open), 54 are phase 2 (46 open), 2 are phase 2/phase 3 (2 open), and 24 are phase 3 (19 open).

HER2 Deficient Expression, HER2 Negative, and ERBB2 Amplification are the most frequent biomarker inclusion criteria for capecitabine clinical trials.

Breast carcinoma, gastric adenocarcinoma, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in capecitabine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Capecitabine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Capecitabine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating capecitabine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Xeloda, capecitabin, capecitabina, 154361-50-9, n(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, xeloda®, pentyl [1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate, capecitabinum, 712807, (1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester, ro 09-1978/000, capecitabine [chemical/ingredient], capecitabine (product), cape, pentyl 1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate, 5'-deoxy-5-fluoro-n-[(pentyloxy)carbonyl]-cytidine, capecitabine (substance), capecitabine, capecitabine
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C1794
SNOMED ID [1]:
F-65511

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.